Trends in Overactive Bladder Prescriptions from 2020 to 2022
Abstract
Importance: There is growing concern regarding the risk of cognitive impairment with anticholinergics to treat overactive bladder (OAB). In 2021, updated clinical guidelines cautioned the use of anticholinergic especially in elderly patients and vibegron became the second available Beta-3 agonist medication. Objective: The primary objective of this study was to examine OAB prescribing patterns from 2020 to 2022. Study Design: This was a retrospective study at two academic centers between January 2020 and December 2022. Female patients at least 18 years old diagnosed with OAB and newly prescribed anticholinergic or Beta-3 for OAB were included. OAB diagnosis was identified using ICD-10 codes and the electronic medical record was queried for new OAB medication prescriptions in the health system. Patient demographics and provider specialty were abstracted from the medical record. Results: Between 2020 and 2022, 12,162 patients were prescribed a new anticholinergic or Beta-3 medication. Older, white patients were more likely to be prescribed Beta-3 medications (p<0.001). Publicly insured patients were more likely to receive a Beta-3 prescription while patients with private insurance were more likely to receive an anticholinergic prescription (p<0.001). Provider specialty was significantly different between Beta-3 and anticholinergic prescriptions (p<0.001). Urogynecologists were the leading prescribers of Beta-3 (33.8%), while PCPs prescribed the most anticholinergic (38.6%).…
Read the paper
Related studies
- Sarcopenia, sarcopenic overweight/obesity and risk of cardiovascular disease and cardiac arrhythmia: A cross-sectional study
- Workplace Violence Is Associated With Impaired Work Functioning in Nurses: An Italian Cross-Sectional Study
- Vagus Nerve Dysfunction in the Post-COVID-19 Condition: a pilot cross sectional study
- Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018
- Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder
- Association between triglyceride glucose‐body mass index and hypertension in Chinese adults: A cross‐sectional study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.